Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413254 | 0.86 | LMNA (0.81) | KMT2ALMNAALOX15MAPK1PLA2G4B | |
| SCHEMBL29953637 | 0.86 | MAOB (0.67) | KMT2ALMNAALOX15MAPK1PKM | |
| SCHEMBL9448407 | 0.86 | LMNA (0.60) | NR4A2KMT2ALMNAALOX15MAPK1 | |
| SCHEMBL5839185 | 0.86 | NR4A2 (0.66) | NR4A2KMT2ALMNAAKR1C3PLA2G4B | |
| SCHEMBL4060556 | 0.86 | MAOB (0.67) | KMT2ALMNAALOX15MAPK1PKM | |
| SCHEMBL12168943 | 0.86 | NR4A2 (0.61) | NR4A2KMT2AAKR1C3PLA2G4BNPC1 | |
| SCHEMBL15093881 | 0.86 | LMNA (0.60) | NR4A2KMT2ALMNAALOX15MAPK1 | |
| SCHEMBL12411431 | 0.86 | KMT2A (0.66) | NR4A2KMT2ALMNAAKR1C3PLA2G4B | |
| SCHEMBL1573075 | 0.86 | NR4A2 (0.61) | NR4A2KMT2AAKR1C3PLA2G4BNPC1 | |
| SCHEMBL5315044 | 0.86 | ALOX15 (0.63) | NR4A2KMT2ALMNAALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023187697-A1 | PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM | GLENMARK LIFE SCIENCES LIMITED (IN) | 2023-10-05 | — | — | WO | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060729-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-0115403-B1 | ABSORBABLE POLYMERS OF SUBSTITUTED BENZOIC ACID | ETHICON, INC. (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4532928-A | RADIATION STERILIZABLE | ETHICON, INC. (US) | 1985-08-06 | — | — | US | disclosed |
| US-4510295-A | POLYESTER COPOLYMERS; FIBERS, SUTURES, SURGICAL PRODUCTS | ETHICON, INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0115403-A1 | Absorbable polymers of substituted benzoic acid | ETHICON, INC. (US) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | NR4A2 3961/4885KMT2A 3670/4885LMNA 3909/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | NR4A2 3961/4885KMT2A 3670/4885LMNA 3909/4885 |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | NR4A2 435/4885KMT2A 3426/4885LMNA 3195/4885 |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | NR4A2 435/4885KMT2A 3426/4885LMNA 3195/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | NR4A2 3961/4885KMT2A 3670/4885LMNA 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.